Buch, Englisch, 472 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 890 g
Buch, Englisch, 472 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 890 g
ISBN: 978-0-12-396492-2
Verlag: William Andrew Publishing
Zielgruppe
medicinal, pharmaceutical, and organic chemists
Fachgebiete
Weitere Infos & Material
Personal Essay
- Reflections on Medicinal Chemistry at Merck, West Point
Paul S. Anderson
- My Path in Seeking New Medicines
Peter R. Bernstein
- Tales of Drug Discovery
M. Ross Johnson
I. Central Nervous System Diseases
Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts
- Recent Developments in Targeting Neuroinflammation in Disease
Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal
- Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease
Harrie J. M. Gijsen and François P. Bischoff
- mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher
- NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments
Kamalesh B. Ruppa, Dalton King and Richard Olson
- Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
Lei Zhang and Anabella Villalobos
II. Cardiovascular and Metabolic Diseases
Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey
- Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler
- AMPK Activation in Health and Disease
Iyassu K. Sebhat and Robert W. Myers
- Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome
Juan C. Jaen, Jay P. Powers and Tim Sullivan
- Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
Philip A. Carpino and David Hepworth
III. Inflammatory Pulmonary and Gastrointestinal Diseases
Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey
- Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
Alaric J. Dyckman
- Bifunctional Compounds for the Treatment of COPD
Gary Phillips and Michael Salmon
- Inflammatory Targets for the Treatment of Atherosclerosis
Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi
IV. Oncology
Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia
- Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook
Paul F. Richardson
- Small-Molecule Antagonists of Bcl-2 Family Proteins
Sean P. Brown and Joshua P. Taygerly
- Notch Pathway Modulators as Anti-Cancer Chemotherapeutics
Vibhavari Sail and M. Kyle Hadden
- Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers
Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda
V. Infectious Diseases
Section Editor: John Primeau, Westford, Massachusetts
- Recent Advances in the Discovery of Dengue Virus Inhibitors
Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand
- Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
Pravin S. Shirude and Shahul Hameed
- HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex
Robert Hamatake, Andrew Maynard and Wieslaw M. Kazmierski
VI. Topics in Biology
Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut
- Antibody-Drug Conjugates for Targeted Cancer Therapy
Victor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert
- 3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug Discovery
Indira Padmalayam and Mark J. Suto
- Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?
Nuska Tschammer
- Recent Advances in Wnt/b-Catenin Pathway Small Molecule Inhibitors
Daniel D. Holsworth and Stefan Krauss
VII. Topics in Drug Design and Discovery
Section Editor: Peter R. Bernstein, PhaRmaB LLC, Rose Valley, Pennsylvania
- Targeted Covalent Enzyme Inhibitors
Mark C. Noe and Adam M. Gilbert
- Drug Design Strategies for GPCR Allosteric Modulators
P. Jeffrey Conn, Scott D. Kuduk and Darío Doller
- Progress in the Development of Non-ATP Competitive Protein Kinase Inhibitors for Oncology
Campbell McInnes
VIII. Trends
Section Editor: Joanne Bronson, Bristol-Myers Squibb, Wallingford, Connecticut
- New Chemical Entities Entering Phase III Trials in 2011
Gregory T. Notte
- To Market, To Market - 2011Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg
